Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BYScientific Reports

Incidence, treatment, and survival of synchronous peritoneal metastases in breast cancer

  • Madelief M. Kieboom1
  • Micha J. de Neijs2
  • Anouk Rijken1
  • Felice N. van Erning1
  • Linda de Munck3
  • Sabine Siesling3
  • Gabe S. Sonke4
  • Ron H. J. Mathijssen2
  • Ignace H. J. T. de Hingh1
4 affiliations
  1. 1Department of Surgery, Catharina Hospital
  2. 2Department of Medical Oncology, Erasmus MC Cancer Institute
  3. 3Department of Research and Development, Netherlands Comprehensive Cancer Organisation
  4. 4Department of Medical Oncology, Netherlands Cancer Institute
Read full textPDFDOICite

Abstract

This nationwide population-based study assessed the incidence, treatment, and survival of patients with synchronous peritoneal metastases (PM) from breast cancer. All patients diagnosed with synchronous metastatic breast cancer between 2009 and 2020 were included from the Netherlands Cancer Registry (NCR). Treatments were categorized into tumor-directed treatment (surgery, systemic chemotherapy, or endocrine therapy), or best supportive care (BSC). Overall survival (OS) was analyzed using multivariable Cox regression. Among 9,353 patients with synchronous metastatic breast cancer, 358 (4%) presented with synchronous PM. In patients with PM, 257 (72%) patients received tumor-directed treatment, predominantly endocrine therapy (n = 146, 57%), chemotherapy (n = 61, 24%), or both (n = 35, 14%), while 101 (28%) patients received BSC. Median OS was higher in patients without peritoneal involvement, 31.1 months, compared to 14.1 months in patients with synchronous PM. The median OS of patients who received BSC was 1.3 months versus 23.6 months for patients who received tumor-directed treatment. Age above 70 years (hazard ratio 1.62 [95% confidence interval 1.18–2.21]) was associated with worse prognosis. Synchronous PM was present in 4% of all metastatic breast cancer patients. Although PM negatively impacted OS compared to metastatic breast cancer patients without PM, the majority (> 70%) received tumor-directed treatment, significantly prolonging OS.

Related

  1. Gastric cancer peritoneal metastases as an immune compartment: immune evasion, systemic immunotherapy and regional treatment strategies
    Eoghan Burke
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMCEurope PMCPMC
  2. A Contemporary Review of Resectability and Treatment Strategies for Colorectal Liver Metastases: Part 1—Diagnosis, Defining Resectability, and Management of Upfront Resectable and Synchronous Disease
    Jennifer A. Kalil, René Adam, Nicholas Meti +1
    CancersPeer-reviewedCC BYFull text1 citedOncologyEurope PMCCrossref
  3. Case Report: Prolonged survival following multimodal treatment of leptomeningeal metastases in triple-negative glycogen-rich clear cell breast carcinoma
    Yun-Chih Lo, Chun-Chieh Wu, Shang-Chun Hung +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  4. Treatment Patterns and Survival in Older Patients with FIGO Stage IIB–IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinomas
    Tingting Zhang, Bing Liang, Cuiqin Sang +4
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Obstetrics, gynaecology & paediatricsCrossref
  5. Synchronous medullary and papillary thyroid carcinoma with mixed-component lateral cervical lymph node metastases: a case report
    Yifan He, Cheng Fu, Yawen Bai +1
    Gland SurgeryPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kieboom2026incidence,
  title = {{Incidence, treatment, and survival of synchronous peritoneal metastases in breast cancer}},
  author = {Madelief M. Kieboom and Micha J. de Neijs and Anouk Rijken and Felice N. van Erning and Linda de Munck and Sabine Siesling and Gabe S. Sonke and Ron H. J. Mathijssen and Ignace H. J. T. de Hingh},
  journal = {Scientific Reports},
  year = {2026},
  month = aug,
  doi = {10.1038/s41598-026-66322-6},
  url = {https://doi.org/10.1038/s41598-026-66322-6},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Incidence, treatment, and survival of synchronous peritoneal metastases in breast cancer
AU  - Madelief M. Kieboom
AU  - Micha J. de Neijs
AU  - Anouk Rijken
AU  - Felice N. van Erning
AU  - Linda de Munck
AU  - Sabine Siesling
AU  - Gabe S. Sonke
AU  - Ron H. J. Mathijssen
AU  - Ignace H. J. T. de Hingh
PY  - 2026
DA  - 2026/08/01
JO  - Scientific Reports
DO  - 10.1038/s41598-026-66322-6
UR  - https://doi.org/10.1038/s41598-026-66322-6
AB  - This nationwide population-based study assessed the incidence, treatment, and survival of patients with synchronous peritoneal metastases (PM) from breast cancer. All patients diagnosed with synchronous metastatic breast cancer between 2009 and 2020 were included from the Netherlands Cancer Registry (NCR). Treatments were categorized into tumor-directed treatment (surgery, systemic chemotherapy, or endocrine therapy), or best supportive care (BSC). Overall survival (OS) was analyzed using multivariable Cox regression. Among 9,353 patients with synchronous metastatic breast cancer, 358 (4%) presented with synchronous PM. In patients with PM, 257 (72%) patients received tumor-directed treatment, predominantly endocrine therapy (n = 146, 57%), chemotherapy (n = 61, 24%), or both (n = 35, 14%), while 101 (28%) patients received BSC. Median OS was higher in patients without peritoneal involvement, 31.1 months, compared to 14.1 months in patients with synchronous PM. The median OS of patients who received BSC was 1.3 months versus 23.6 months for patients who received tumor-directed treatment. Age above 70 years (hazard ratio 1.62 [95% confidence interval 1.18–2.21]) was associated with worse prognosis. Synchronous PM was present in 4% of all metastatic breast cancer patients. Although PM negatively impacted OS compared to metastatic breast cancer patients without PM, the majority (> 70%) received tumor-directed treatment, significantly prolonging OS.
SN  - 2045-2322
ER  -